key: cord-0914475-n0rm1a01 authors: Kerget, Buğra; Çelik, Eda; Kerget, Ferhan; Aksakal, Alperen; Uçar, Elif Yılmazel; Araz, Ömer; Akgün, Metin title: Evaluation of 3‐month follow‐up of patients with postacute COVID‐19 syndrome date: 2022-01-18 journal: J Med Virol DOI: 10.1002/jmv.27579 sha: 0954a5eb86d7b8e82a7853d25a73b6daefbdfac1 doc_id: 914475 cord_uid: n0rm1a01 In addition to the highly variable clinical presentation of acute COVID‐19 infection, it can also cause various postacute signs and symptoms. This study aimed to evaluate patients with postacute COVID‐19 over 12 weeks of follow‐up. The study included 151 patients who were diagnosed with COVID‐19 by real‐time polymerase chain reaction of a nasopharyngeal swab 1 month earlier, had radiologic findings consistent with COVID‐19 pneumonia, and presented to the post‐COVID‐19 outpatient clinic between May and August 2021. The patients were divided into three groups based on COVID‐19 severity: nonsevere pneumonia (Group 1), severe pneumonia (Group 2), and severe pneumonia requiring intensive care (Group 3). Evaluation of laboratory parameters at 4 and 12 weeks showed that Group 3 had a higher lactose dehydrogenase (LDH) level and a lower mean platelet volume than the other groups at both time points (p = 0.001 for all). Group 3 also had lower percent predicted forced vital capacity (FVC%), percent predicted forced expiration volume in 1 s (FEV1%), and percent predicted diffusion capacity of the lungs for carbon monoxide divided by alveolar volume (DLCO/VA%) compared to Groups 1 and 2 at Week 4 (p = 0.001, 0.004, 0.001, respectively) and compared to Group 1 at 12 weeks (p = 0.002, 0.03, 0.001, respectively). Patients with persistent dyspnea at 12 weeks had significantly lower FEV1%, FVC%, DLCO/VA%, and saturation levels in room air and significantly higher LDH, pro‐BNP, D‐dimer, and heart rate compared to those without dyspnea (p = 0.001 for all). Although the lungs are most commonly affected after COVID‐19 infection, vascular and endothelial damage also causes multisystem involvement. Our study indicates that laboratory values, radiological signs, and pulmonary functional capacity improved in most patients after 12 weeks of follow‐up. There have been over 200 hundred million confirmed cases of novel coronavirus disease 2019 since the disease first appeared in December 2019, and this figure continues to rise. While many infected individuals are asymptomatic or have mild symptoms such as fatigue, muscle and joint pain, decreased appetite, and loss of smell and taste, severe illness can occur, particularly in advanced age, in the presence of comorbidities such as hypertension, diabetes mellitus, or chronic kidney disease, in states of immunosuppression or immunocompromise, and in pregnancy. 1, 2 The most common severe clinical manifestations of COVID-19 are acute respiratory failure and macrophage activation syndrome. Both are characterized by excessive cytokine release, which can cause endothelial and vascular dysfunction in many vital organs, especially the lungs. 3 The lungs are primarily affected in COVID-19 patients due to alveolar epithelial destruction, capillary damage/hemorrhage, hyaline membrane formation, alveolar septal fibrous proliferation, and pulmonary consolidation. 4 Furthermore, persistent signs of damage in many organs and tissues after the active infection may necessitate long-term medical treatment. The term "postacute COVID-19 syndrome" has been used to describe symptoms and abnormalities that persist up to 12 weeks after the onset of acute COVID- 19 and cannot be attributed to alternative diagnoses. 5 Extrapulmonary effects in patients with postacute COVID-19 syndrome include symptoms such as chest pain, myocardial dysfunction, venous thromboembolism, myalgia, weight loss, asthenia, hair loss, diarrhea, anosmia or parosmia, posttraumatic stress, depression, and anxiety. The main pulmonary signs and symptoms consist of dyspnea, cough, chronic oxygen dependence, dysfunctional breathing, and radiological sequelae. 6 In a study evaluating COVID-19 patients after discharge, greater disease severity was associated with lower diffusion capacity, whereas forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) did not differ significantly between patients who had mild, moderate, and severe pneumonia. 7 In addition, in our previous study evaluating the relationship between laboratory parameters and pulmonary function tests during active COVID-19 infection, we observed that FEV1 and FVC levels increased in correlation with the decline in C-reactive protein and fibrinogen levels. 4 In the present study, we aimed to examine changes in clinical symptoms, laboratory parameters, and pulmonary function tests over 12 weeks of follow-up in patients presenting to our COVID-19 outpatient clinic due to postacute COVID-19 syndrome. pants were informed about the study purpose, methods, and time investment needed for their participation in the study. The participants were also informed that the study carried no risk, their participation was completely voluntary, and they could withdraw from the study at any time. The study included patients with and without comorbidities who were diagnosed with COVID-19 by real-time polymerase chain reaction test of a nasopharyngeal swab 1 month earlier, had persistent symptoms associated with postacute COVID-19, and met the following additional criteria: 1. Were over 18 years of age. 2. Had radiological findings consistent with COVID-19 pneumonia. 3. Did not need intubation and mechanical ventilation. 4. Agreed to attend follow-up appointments within the 12-week study period. Patients who violated the inclusion criteria or met any of the following criteria were excluded: 1. Any potential contraindications to pulmonary function testing (recent myocardial infarction, pulmonary embolism, cerebral aneurysm, active hemoptysis, pneumothorax, nausea/vomiting, recent thoracic, abdominal, or ocular surgery). 3. Previously known or newly detected lung pathology. The patients included in the study were divided into three groups according to COVID-19 severity and follow-up. Patients in Group 1 had nonsevere pneumonia (n = 83), patients in Group 2 had severe pneumonia but did not require intensive care due to respiratory failure or macrophage activation syndrome (n = 34), and patients in Group 3 had severe pneumonia and were admitted to the intensive care unit due to respiratory failure or macrophage activation syndrome (n = 34). Severe pneumonia was defined as meeting any of the following criteria: respiratory rate of 30 breaths/min or higher, oxygen saturation of 92% or lower, and more than 50% lung infiltration. Patients presenting to the post-COVID outpatient clinic were registered and their history was obtained. Their smoking history was ascertained and the number of pack-years was calculated. The route of COVID-19 transmission was noted. Physical examination was performed and the patients were asked about common symptoms such as fever, shortness of breath, cough, fatigue, loss of taste/smell, joint/ muscle pain, headache, sore throat, diarrhea, hair loss, and psychiatric disorders. Complete blood count was performed in the biochemistry laboratory. At 4 and 12 weeks after testing positive for COVID-19, routine hemogram and biochemical tests were requested and pulmonary function tests including diffusion capacity of the lungs for carbon monoxide (DLCO) were performed. Patients were instructed to wear light clothing and abstain from smoking for 24 h, alcohol for 4 h, heavy meals for 2 h, and strenuous exercise for 30 min before testing. Pulmonary function tests were performed by the same technician using a Plusmed MIR Spirolab III device with body temperature and pressure saturated with water vapor correction according to room air and barometric pressure. Testing was done in negative-pressure room using protective equipment to prevent COVID-19 transmission. The patients' age, height, and weight were recorded and the technician explained the expected maneuver to the patients. Three acceptable spirograms were obtained and those that met the 2019 American Thoracic Society/European Respiratory Society reproducibility and acceptability criteria were included in the study. 8 The lower limits of the normal range determined for the healthy population according to the criteria specified in the same report were also calculated and presented by the spirometry device. Posterior-anterior chest X-rays were obtained from all patients in the study at 4-and 12-week follow-up and the findings were classified as follows: Complete resolution: Chest X-ray was normal or returned to pre-COVID-19 state. Major improvement: Resolution of more than 50% of pulmonary opacities that developed during acute COVID-19. Minor improvement or no change: Resolution of less than 50% of pulmonary opacities that developed during acute COVID-19. Worsening: Increased alveolar opacities or development of pulmonary fibrosis despite resolution of alveolar opacities that developed during acute COVID-19. For patients with increased parenchymal consolidations during treatment and follow-up, thoracic computed tomography was performed to confirm whether their current condition could be contributed to non-COVID-19 causes. Tomographic evaluation was not included in routine follow-up for all patients. Patients who presented for post-acute COVID-19 with complaints of myalgia, malaise, diarrhea, loss of taste/smell, and brain fog were followed without treatment. Patients in Group 3, who presented due to cough and dyspnea, exhibited diffusion values lower than 80% on pulmonary function test or oxygen saturation of 92% or lower in room air. All of these patients were treated with methylprednisolone starting at a dose of 0.5 mg/kg/day and reduced according to clinical and laboratory parameters until discontinuation at 12 weeks. Long-term homeoxygen therapy was recommended for patients with partial pressure of oxygen below 55 mmHg or oxygen saturation below 88% with or without hypercapnia. Patients presenting with cough and limited diffusion without oxygen desaturation but with forced expiratory flow at 25% and 75% of pulmonary volume (FEF25-75%) lower than 80% were given low-dose steroid inhaler or montelukast 10 mg/day. For patients with palpitations, the cardiology department was consulted to evaluate for cardiac involvement. Analyses were performed using IBM SPSS version 20.0 software (IBM Corp.). Data were presented as mean, standard deviation, number, and percentage. Shapiro-Wilk test and Kolmogorov-Smirnov test were used to determine whether continuous variables were normally distributed. Independent samples t-test was used to compare two independent groups, and Wilcoxon test was used to analyze dependent variables. Independent samples t-test was used to compare two independent groups. Continuous variables were compared between more than two independent groups using analysis of variance (ANOVA) if normally dis- The mean age of the participants was 48 ± 12.4 years. The mean ages in Groups 1, 2, and 3 were 46.4 ± 14.2, 51.8 ± 6.5, and 48.1 ± 11. Week 12 Week 4 Week 12 Week 4 Week 12 Comparison of laboratory and pulmonary function test parameters between patients with and without postacute COVID-19 syndrome at Week 12 of follow-up is shown in Table 3 . Patients with postacute COVID-19 syndrome had significantly higher white blood cell count, neutrophil count, LDH, D-dimer, and pro-BNP levels, and heart rate (p = 0.001, 0.001, 0.002, 0.001, 0.001, and 0.01, respectively) and significantly lower MPV, FEV1%, FVC%, DLCO/VA%, and T A B L E 2 Comparison of pulmonary function test results, saturation levels, and heart rate in postacute COVID-19 patients at 4 and 12 weeks Group 1 (n = 83) Group 1 (n = 83) Group 2 (n = 34) Group 2 (n = 34) Group 3 (n = 34) Group 3 (n = 34) Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Week 4 Week Symptom frequency at Weeks 4 and 12 is shown in Figure 1 . At Week 4, dyspnea was reported more frequently by patients in Group 3 than patients in Groups 1 and 2 (p < 0.05). Myalgia, fatigue, and cough were more common in Groups 2 and 3 compared to Group 1, while hair loss and brain fog were more common in Group 2 compared to Groups 1 and 3 (p < 0.05 for all). At Week 12 of follow-up, dyspnea and myalgia were more frequent in Group 3 compared to Groups 1 and 2, while fatigue was more common in Groups 2 and 3 compared to Group 1 (p < 0.05 for all). The change in radiological findings by week is shown in Figure 2 . Week 12 were associated with significant differences in FEV1%, FVC %, and DLCO/VA%, as well as LDH, pro-BNP, D-dimer, oxygen saturation in room air, and heart rate compared to those in patients without dyspnea (p = 0.001 for all) (Figure 3 ). In this study, we observed that men comprised a significantly higher proportion of patients who developed macrophage activation syndrome or respiratory failure. In addition, hypertension and diabetes were found to be the most common comorbidities in patients who were hospitalized for COVID-19. Consistent with previous reports The etiology of postacute symptoms after COVID-19 may be attributable to multifactorial causes. The neuroinvasive property of the SARS-CoV-2 virus has been proposed as a factor contributing to symptoms such as loss of taste and smell and the brain fog observed after COVID-19. 17, 18 It has also been emphasized that cytokine storm, the term for extreme pro-inflammatory cytokine production that occurs frequently in COVID-19 patients, may be responsible for symptoms in the postacute period. Another possibility is that the virus localizes to immunologically privileged sites and cannot be completely eradicated by the immune system. 6 In postmortem studies of COVID-19 patients, the presence of severe endothelial damage, thrombosis, and microangiopathy in the peripheral lung tissue are the main histopathologic signs explaining the subsequent organ damage. 19 A radiological study of COVID-19 patients after discharge showed that ground glass opacities with areas of consolidation and subpleural fibrotic bands persisted at 3-month follow-up, while a substantial proportion of patients had fibrotic areas with or without parenchymal destruction at 6-month follow-up. 20 | 2033 COVID-19 pathophysiology: a review What are the risks of COVID-19 infection in pregnant women? Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID-19 patients Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls Post-acute COVID-19 syndrome Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement Postviral fatigue syndrome Ross River Virus immune evasion strategies and the relevance to post-viral fatigue, and myalgic encephalomyelitis onset Post-infectious fatigue syndrome in dengue infection Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines Active Epstein-Barr virus infection in post-viral fatigue syndrome Postacute COVID-19: an overview and approach to classification. Paper presented at: open Forum Infectious Diseases Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome Vertigo and hearing loss during the COVID-19 pandemic-is there an association? Postacute sequelae of COVID-19: evidence of mood & cognitive impairment Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect Evaluation of 3-month follow-up of patients with postacute COVID-19 syndrome The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request.